MediCapital Rent Is Now Emsere
MediCapital Rent, a medical equipment solutions provider for clinical trials, today announced the company will begin operating under a new name, Emsere.
Emsere provides customers with proactive trial equipment solutions and manages those solutions with a single point of contact for all questions and support. Their global coverage with customs clearance and personalized study tracking of budget, inventory and delivery details provide exceptional, personalized service from study startup to study completion and all phases in between. Emsere’s equipment, supplies and software solutions extend to thousands of products, a rental fleet with over ten thousand devices and serving over 9,000 investigator sites to customers all over the world.
To read more about Emsere and their full range of capabilities, visit the company’s website.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
